AAP Grand Rounds Subscribe to Pediatrics in Review
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 14 No. 2, August 2005
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schonwald, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Schonwald, A.
Related Collections
Right arrow Clinical Pharmacology and Therapeutics
Right arrow Developmental and Behavioral Pediatrics

AAP Grand Rounds 14:15 (2005)
© 2005 American Academy of Pediatrics

DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS

The Methylphenidate Patch: The Next New Treatment for ADHD?

Source: Pelham WE, Manos MJ, Ezzelli CE, et al. A doseranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44:522–529.[Medline]

The first 20% of the full text of this article appears below.

These researchers from the State University of New York at Buffalo, Cleveland Clinic Children’s Hospital, and the Medical University of South Carolina report the results of a dose-ranging study of transdermal methylphenidate (MPH). The study was supported by Noven Pharmaceuticals, the developer of this transdermal delivery system. The double-blinded, 8-day, within-subject placebo-controlled evaluation included 36 children (aged 6 to 13 years, mean=9.6 years) at 3 summer treatment sites. All children had attention deficit hyperactivity disorder (ADHD), and 58% were previously treated with stimulants. The children were mostly white (75%) and male (92%). Each day, parents applied a patch containing 1 of 3 MPH doses or placebo. Patches were . . . [Full Text of this Article]

Alison Schonwald, MD, FAAP
Developmental Medicine Center, Children’s Hospital, Boston, MA

 





HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Academy of Pediatrics.